DAY ONE BIOPHARMACEUTICALS
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer. Day One Biopharmaceuticals also focuses its efforts to bring the best m... edicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies. Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA.
DAY ONE BIOPHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2018-11-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.dayonebio.com
Total Employee:
51+
Status:
Active
Contact:
+1 650 484 0899
Email Addresses:
[email protected]
Total Funding:
362.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Font Awesome
Similar Organizations
Clover Biopharmaceuticals
Clover Biopharmaceuticals is a clinical-stage biotechnology company focused on developing vaccines and biologic therapeutic.
Regeneron
Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Umoja Biopharma
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Wren Therapeutics
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Atlas Venture
Atlas Venture investment in Series B - Day One Biopharmaceuticals
Franklin Templeton Investments
Franklin Templeton Investments investment in Series B - Day One Biopharmaceuticals
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Day One Biopharmaceuticals
T. Rowe Price
T. Rowe Price investment in Series B - Day One Biopharmaceuticals
Canaan Partners
Canaan Partners investment in Series B - Day One Biopharmaceuticals
Access Biotechnology
Access Biotechnology investment in Series B - Day One Biopharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Series B - Day One Biopharmaceuticals
Boxer Capital
Boxer Capital investment in Series B - Day One Biopharmaceuticals
Viking Global Investors
Viking Global Investors investment in Series B - Day One Biopharmaceuticals
RA Capital Management
RA Capital Management investment in Series B - Day One Biopharmaceuticals
Official Site Inspections
http://www.dayonebio.com Semrush global rank: 2.7 M Semrush visits lastest month: 6.15 K
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Day One Biopharmaceuticals"
About Us - Day One Bio
You are now leaving the Day One Biopharmaceuticals Corporate Website. You will now be redirected to the requested website. Please confirm that you want to proceed.See details»
Day One Biopharmaceuticals | Leadership
Michael serves as an advisor to several organizations, including as member of the Corporate Advisory Committee for National Tay Sachs and Allied Diseases, a national organization focused on funding research, promoting awareness, and …See details»
Day One Biopharmaceuticals - Crunchbase Company …
Contact Email [email protected] Phone Number +1 650 484 0899 Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.See details»
Day One Announces Two New Appointments to Board of Directors
Jan 17, 2024 The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). …See details»
Day One Biopharmaceuticals Company Overview, Contact Details ...
Jul 30, 2024 Dayonebio partners with Sprint Bioscience AB. BRISBANE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage …See details»
Day One Biopharmaceuticals | LinkedIn
Day One Biopharmaceuticals Biotechnology Research Brisbane, California 16,643 followers Cancer drug development comes of age.See details»
Day One Appoints Saira Ramasastry to Board of Directors
Apr 12, 2021 Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco. For more information, please visit …See details»
Day One Reports First Quarter 2023 Financial Results and …
May 1, 2023 Lauren Merendino, MBA, will lead Day One’s commercial organization as Chief Commercial Officer (CCO) and will focus on finalizing preparations for the commercial launch …See details»
Day One | Advancing Targeted Therapies | Our Culture
Get to know the culture at Day One, a clinical-stage company advancing targeted therapies for people of all ages with life-threatening diseases.See details»
Day One Biopharmaceuticals CEO and Key Executive Team
Day One Biopharmaceuticals's Chief Executive Officer and Director is Jeremy Bender. Other executives include Lisa Bowers, Chief Commercial Officer; Mike Preigh, Chief of Technology …See details»
Day One Biopharmaceuticals - Company Profile & Staff Directory
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a …See details»
Day One | Advancing Targeted Therapies | Mission & Strategy
Day One Biopharmaceuticals is a clinical-stage company committed to advancing targeted therapies for people of all ages with life-threatening diseases.See details»
Day One Appoints Scott Garland to Board of Directors
Aug 17, 2021 SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company …See details»
Navigating Day One Biopharmaceuticals' Financial Health And …
Ir.dayonebio.com. However, ... the creation of a national sales force is a sign that the organization is ready to face this challenge head-on. The strategic positioning of the company in terms of ...See details»
Day One Biopharmaceuticals - Craft
Oct 10, 2024 Revenue (Q3, 2024)$93.8M Net income (Q3, 2024)$37.0M Cash (Q3, 2024)$422.8M EBIT (Q3, 2024)$29.6M Enterprise value $1.1BSee details»
Day One Announces Retirement of Dr. Samuel Blackman, Co …
Nov 20, 2024 Dr. Blackman’s departure planned for end of 2024. Company’s search for a new Head of R&D is ongoing. BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One …See details»
Day One Biopharmaceuticals | Patients, Families & Advocates
Advancing Pediatric Cancer Research and Drug Development Through Multistakeholder Collaboration. By sharing this Framework, we hope to prompt further discussions and greater …See details»
Day One Announces $130 Million Series B Financing to Accelerate …
Feb 10, 2021 For more information, please visit www.dayonebio.com. 1 Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566 Contacts. 1AB Dan …See details»
Day One Expands Pipeline with Potential First-in-Class Clinical …
Jun 18, 2024 For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X. Cautionary Note Regarding Forward-Looking Statements This press release …See details»